Published December 16, 2025 | Version v1
Journal article Open

SOMATOTROP YETISHMOVCHILIGI BOR BOLALARDA SINTETIK SOMATOTROPIN ANALOGLARI FONIDA BO'Y O'SISH DINAMIKASI

Authors/Creators

  • 1. assistent, Department of Endocrinologi, Samarkand State Medical University, Samarkand , Republic of Uzbekistan

Description

Somatotrop yetishmovchiligi (SY), shuningdek, growth hormone deficiency (GHD) nomi bilan ma'lum, bolalarda o'sish gormonining yetarli darajada ishlab chiqarilmasligi bilan bog'liq endokrin kasallik bo'lib, bu holat bo'y o'sishining sekinlashuviga, yakuniy bo'yining past bo'lishiga va psixososial rivojlanishdagi muammolarga olib keladi. Sintetik somatotropin analoglari, xususan rekombinant inson o'sish gormoni (rhGH), bu kasallikni davolashda asosiy usul hisoblanadi va bolalarning bo'y o'sish dinamikasini sezilarli darajada yaxshilaydi. Ushbu obzor maqola PubMed, PMC, Scopus va boshqa yuqori indekslangan ma'lumotlar bazalaridagi so'nggi sistematik obzorlar, meta-tahlillar va klinik tadqiqotlardan foydalangan holda, rhGH ning bolalardagi bo'y o'sish dinamikasiga, jumladan o'sish tezligi (height velocity, HV), bo'y standart deviyatsiya skori (height SDS, HSDS) va yakuniy kattalar bo'yiga (adult height, AH) ta'sirini batafsil tahlil qiladi. Natijalar shuni ko'rsatadiki, davolashning birinchi yilida HV o'rtacha 8-12 sm/yilga yetishi mumkin, keyingi yillarda esa 4-7 sm/yilga pasayadi, bu normal o'sish tezligiga yaqinlashadi. Yakuniy AH SDS treated guruhda o'rtacha -2,5 dan -0,3 ga yaqinlashadi, bu normal diapazonga (0 ± 2 SDS) yaqinlashishni anglatadi va untreated guruhga nisbatan 4-8 sm farqni ta'minlaydi. Yuqori dozalar (0,025-0,07 mg/kg/hafta) samaraliroq bo'lib, ammo individual omillar, masalan, yosh (davolashni erta boshlash yaxshiroq natija beradi), boshlang'ich bo'y SDS, pubertal holat, suyak yoshi (bone age), metabolik ko'rsatkichlar (insulin qarshiligi, tiroid gormonlari, hemoglobin, IGF-1 darajasi) va genetik faktorlar (masalan, GH1 geni mutatsiyalari) ta'sir qiladi. Davolash xavfsizligi yuqori, jiddiy nojo'ya ta'sirlar (masalan, intrakranial gipertenziya, neoplazma rivojlanishi) kam (1-2% dan kam), ammo in'ektsiya joyidagi lokal reaktsiyalar va vaqtinchalik IGF-1 oshishi tez-tez uchraydi. Ushbu obzor rhGH ning qisqa muddatli (birinchi 6-12 oy) va uzoq muddatli (5-10 yil) natijalarini, shuningdek, kunlik va haftalik (pegylated) dozalash usullarini taqqoslaydi, GHD va idiopathic short stature (ISS) o'rtasidagi farqlarni ko'rib chiqadi (GHD da natijalar 20-30% yaxshiroq). Bundan tashqari, davolashning farmakoekonomik jihatlari (xarajat-samaradorlik), monitoring usullari (IGF-1 va IGFBP-3 o'lchovlari, suyak yoshi rentgeni) va kelajakdagi tadqiqot yo'nalishlari (gen terapiyasi, yangi LAGH formulalari) muhokama qilinadi. Obzor 1990-2025 yillardagi 100 dan ortiq tadqiqotni qamrab oladi va pediatrik endokrinologlar uchun klinik amaliyot bo'yicha batafsil tavsiyalar beradi, jumladan dozani individualizatsiya qilish va davolash muddatini optimallashtirish.

Files

781-789.pdf

Files (1.1 MB)

Name Size Download all
md5:82d725ed4f55a45bcf1298827452e9d2
1.1 MB Preview Download

Additional details

References

  • 1. Imperiale, T. F., Speroff, T., Marrero, U., Radcliffe, D. J., & Cuttler, L. (2002). Effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Archives of Pediatrics & Adolescent Medicine, 156(3), 230–240. https://doi.org/10.1001/archpedi.156.3.230
  • 2. Ranke, M. B. (2021). Short and long-term effects of growth hormone in children and adolescents with GH deficiency. Frontiers in Endocrinology, 12, Article 720419. https://doi.org/10.3389/fendo.2021.720419
  • 3. Kim, J. H., Chae, H. W., Chin, S. O., Ku, C. R., Park, K. H., Lim, D. J., ... & Lee, E. J. (2020). Diagnosis and treatment of growth hormone deficiency: A position statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology. Endocrinology and Metabolism (Seoul), 35(2), 272–287. https://doi.org/10.3803/EnM.2020.35.2.272
  • 4. Tavares, A. B. W., & Collett-Solberg, P. F. (2021). Growth hormone deficiency and the transition from pediatric to adult care. J Pediatr (Rio J), 97(6), 595–602. https://doi.org/10.1016/j.jped.2021.02.007
  • 5. Zhong, X., Chen, Y., Liu, G., Cui, Z., Luo, K., Wu, Z., Xiao, K., & Li, H. (2025). Metabolic factors influencing the efficacy of recombinant human growth hormone therapy in children with short stature. Frontiers in Endocrinology, 16, Article 1691509. https://doi.org/10.3389/fendo.2025.1691509